PRPO logo.png
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
September 22, 2020 10:30 ET | Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...
IN8bioLogo.jpg
IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
September 17, 2020 07:00 ET | IN8bio, Inc.
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...
Starton logo-pantone2112C.jpg
Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors
September 09, 2020 07:45 ET | Starton Therapeutics, Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel...
jpg.jpg
Incysus Therapeutics to Present at LifeSci Partners Summer Symposium
August 03, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Aprea logo 445pt.png
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
July 16, 2020 07:00 ET | Aprea Therapeutics
Commenced expansion cohort in combination with venetoclax and azacitidineAdded cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics,...
Aptose Biosciences Inc. logo
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
June 29, 2020 07:01 ET | Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
AB Science annonce que les résultats précliniques de la molécule AB8939 dans la leucémie myéloïde aiguë seront présentés au Congrès Annuel de l'Association Européenne d'Hématologie
June 10, 2020 15:23 ET | AB Science
Paris, 10 juin 2020, 21h Les résultats précliniques de la molécule AB8939 dans la leucémie myéloïde aiguëseront présentés au Congrès Annuel de l'Association Européenne d'Hématologie (AEH) ...
AB Science announces that results from AB8939 preclinical program in acute myeloid leukemia will be presented at the European Hematology Association 2020 Annual Congress
June 10, 2020 15:23 ET | AB Science
Paris, 10 June 2020, 9pm Results from AB8939 preclinical program in acute myeloid leukemia presented at the European Hematology Association (EHA) 2020 Annual Congress AB Science SA (Euronext...
jpg.jpg
Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
May 12, 2020 07:00 ET | Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Aptose Biosciences Inc. logo
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
April 27, 2020 09:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...